BTAI vs DAL · rev $388.0K vs P/E 12, rev $35.61B
BioXcel Therapeutics Inc (BTAI) versus Delta Air Lines Inc (DAL) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported DAL revenue for 2026-06-30 was $35.61B. Net income was $1.31B. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
BTAI currently screens at market cap $36.1M. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Not investment advice. Open the BTAI and DAL stock pages for the full models.
Not investment advice.